Phase II study of Bendamustine-Rituximab therapy for CD20-positive untreated and advanced follicular lymphoma with poor response to R-CHOP therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Cyclophosphamide; Doxorubicin; Filgrastim; Prednisolone; Rituximab; Vincristine; Vincristine
Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms Bendamustine Convert Study; CONVERT

01 Feb 2022 Results identifying the molecular biomarkers that can predict prognosis in RB-treated patients in the context of the prospective cohort published in the Cancer Science
28 Oct 2021 Status changed from active, no longer recruiting to completed.
01 Aug 2021 Primary endpoint (Progression free survival rate of 3 years of BR therapy enforcement group) has been met, as per results published in the International Journal of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com